Access to high-cost drugs for advanced breast cancer in Latin America, particularly trastuzumab
Carlos Henrique Barrios, Tomás Reinert and Gustavo Werutsky
PET-CT has low specificity for mediastinal staging of non-small-cell lung cancer in an endemic area for tuberculosis: a diagnostic test study (LACOG 0114)
Gustavo Werutsky, Bruno Hochhegger, José Antônio Lopes de Figueiredo Pinto, Jeovany Martínez-Mesa, Mara Lise Zanini, Eduardo Herz Berdichevski, Eduardo Vilas, Vinícius Duval da Silva, Maria Teresa Ruiz Tsukazan, Arthur Vieira, Leandro Genehr Fritscher, Louise Hartmann, Marcos Alba, Guilherme Sartori, Cristina Matushita, Vanessa Bortolotto, Rayssa Ruszkowski do Amaral, Luís Carlos Anflor Junior, Facundo Zaffaroni, Carlos H. Barrios, Márcio Debiasi and Carlos Cezar Frietscher
Stage III Non-Small-Cell Lung Cancer Treated With Concurrent Chemoradiation Followed or Not by Consolidation Chemotherapy: A Survival Analysis From a Brazilian Multicentric Cohort.
Vladmir C. Cordeiro de Lima, Clarissa S. Baldotto, Carlos H. Barrios, Eldsamira M. Sobrinho, Mauro Zukin, Clarissa Mathias, Facundo Zaffaroni, Rodrigo C. Nery, Gabriel Madeira, Alex V. Amadio, Juliano C. Coelho, Guilherme Geib, Maria Fernanda Simões, and Gilberto Castro Jr
Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor-Positive Breast Cancer
Matissek KJ, Onozato ML, Sun S, Zheng Z, Schultz A, Lee J, Patel K, Jerevall PL, Saladi SV, Macleay A, Tavallai M, Badovinac-Crnjevic T, Barrios C, Be?e N, Chan A, Chavarri-Guerra Y, Debiasi M, Demirdögen E, Egeli Ü, Gökgöz S, Gomez H, Liedke P, Tasdelen I, Tolunay S, Werutsky G, St Louis J, Horick N, Finkelstein DM, Le LP, Bardia A, Goss PE, Sgroi DC, Iafrate AJ, Ellisen LW.
Lung cancer in Brazil
Araujo LH, Baldotto C, Castro G, Katz A, Ferreira CG, Mathias C, Mascarenhas E, Lopes GL, Carvalho H, Tabacof J, Martínez-Mesa J, Viana LS, Cruz MS, Zukin M, Marchi P, Terra RM, Ribeiro RA, Lima VCC, Werutsky G, Barrios CH
Exploring disparities in incidence and mortality rates of breast and gynecologic cancers according to the Human Development Index in the Pan-American region
Martínez-Mesa J, Werutsky G, Stefan M, Pereira Filho CAS, Dueñas-González A, Zarba JJ, Mano M, Villarreal-Garza C, Gómez H, Barrios CH.
Estratégias para vencer a resistência à terapia anti-HER2
Márcio Debiasi, Paulo Nunes Filho, Carolina Albuquerque e Valeria Sgnaolin
Estimation of Premature Deaths From Lack of Access to Anti-HER2 Therapy for Advanced Breast Cancer in the Brazilian Public Health System
Márcio Debiasi, Tomás Reinert, Rafael Kaliks, Gilberto Amorim, Maira Caleffi, Carlos Sampaio, Gustavo dos Santos Fernandes and Carlos H. BarriosJournal of Global Oncology 3, no. 3 (June 2017) 201-207. Full link: https://ascopubs.org/doi/full/10.1200/JGO.2016.005678
Exploiting HPV-induced carcinogenesis for a rational drug development in cervical cancer.
Nogueira-Rodrigues A, Melo AC, Werutsky G, Garces AH, Ferreira CG.
A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study)
Novel targeted agents and combinations have become available in multiple lines of treatment for human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC). In this context, alternatives to the lapatinib (L) and capecitabine (C) regimen, evaluating L combined with other cytotoxic drugs, are warranted.